~99%screen negative
Continue routine screening.
No cancer-associated signal was found in this sample. Cancer can still be present, so keep recommended screening and discuss new symptoms with your clinician.
Galleri® Multi-Cancer Early Detection Test
Screen for 50+ cancer types.
With one blood draw.
One-time test · HSA/FSA eligible, subject to your plan.
Use alongside recommended cancer screening. Galleri can miss cancer or produce false positives. Not available through Empirical in NY, NJ, RI, or AZ.
What types of cancer does GRAIL Galleri detect?
Galleri looks for a signal shared by more than 50 cancer types. Detection varies by cancer type and stage.
See detection rates by cancer type
Sensitivity is the share of people with cancer whose test detects a signal. The CCGA case-control study reported 51.5% sensitivity overall and 99.5% specificity (0.5% false positives among people without cancer). These are study results, not your personal probability of detection.
| Cancer category | Sensitivity |
|---|---|
| Liver / bile duct | 93.5% |
| Head and neck | 85.7% |
| Esophagus | 85.0% |
| Pancreas | 83.7% |
| Ovary | 83.1% |
| Colorectal | 82.0% |
| Anus | 81.8% |
| Cervix | 80.0% |
| Urothelial tract | 80.0% |
| Lung | 74.8% |
| Plasma cell neoplasm | 72.3% |
| Gallbladder | 70.6% |
| Stomach | 66.7% |
| Sarcoma | 60.0% |
| Lymphoma | 56.3% |
| Other | 50.8% |
| Melanoma | 46.2% |
| Lymphoid leukemia | 41.2% |
| Bladder | 34.8% |
| Breast | 30.5% |
| Uterus | 28.0% |
| Myeloid neoplasm | 20.0% |
| Kidney | 18.2% |
| Prostate | 11.2% |
| Thyroid | 0.0% |
The 0% thyroid result means no thyroid cancers were detected in this study sample, not that detection is impossible. CCGA enrolled people with known cancer and is not a prospective screening study. GRAIL’s published sensitivity table.
Galleri can miss cancer, especially at earlier stages.
Who is the Galleri test recommended for?
GRAIL recommends Galleri for adults with elevated cancer risk, such as people age 50 or older; a clinician should determine whether it fits your medical history. It is not recommended during pregnancy, at age 21 or younger, or during active cancer treatment, and symptoms should be evaluated by a clinician rather than waiting for screening.
2,000 testing locations
Choose a Quest location for your blood draw.
Galleri is not available through Empirical in New York, New Jersey, Rhode Island, or Arizona.
Choose your state to browse Quest locations, then narrow by city or street.
Our directory may not include recent location changes. For the complete current network and appointments, visit the Quest location finder. Order through Empirical before your visit and bring your requisition.
What do Galleri test results mean?
~1%of adults ages 50–79
Arrange diagnostic follow-up.
A signal is not a cancer diagnosis. Your clinician uses the predicted Cancer Signal Origin (CSO)—the tissue or organ the signal likely came from—to plan further evaluation, which may include imaging or a biopsy. In the initial PATHFINDER 2 results, about 62% of people with a positive result had cancer confirmed after diagnostic evaluation.
Junction’s clinical team helps you interpret your result and the next steps.
Sources: GRAIL’s results guide and our evidence review. The 99%/1% estimates and 62% figure come from different study populations; the latter is from the initial PATHFINDER 2 analysis. These figures do not predict an individual’s result.
A closer look at the evidence and cost
Some questions we’ve heard before
A broader look at cancer. One blood draw.
Galleri by GRAIL. $849 for a one-time test.
